The Phase 3 BASIS trial assessed the efficacy and safety of marstacimab, a monoclonal antibody targeting the tissue factor pathway inhibitor, in participants with severe haemophilia A or moderately severe to severe haemophilia B without inhibitors. The study demonstrated marstacimab’s effectiveness in reducing bleeding events compared to previous therapies, along with its safety profile over […]

In KMT2Ar leukaemia, the interaction between menin and KMT2A fusion proteins plays a crucial role in the development of the disease. Despite this, there are currently no approved therapies targeting the menin-KMT2A interaction. Dr Ibrahim Aldoss (City of Hope National Medical Center, Duarte, CA, USA) joins us to discuss revumenib, a novel small-molecule inhibitor targeting […]

The Renoir phase 3 study investigates the efficacy of combining rituximab and lenalidomide versus rituximab alone for relapsed/refractory (R/R) follicular lymphoma in elderly patients, in whom treatment options are typically limited. Lenalidomide, known for its direct anti-tumor and antiangiogenic effects, and ability to modulate the tumor-cell microenvironment, presents a viable option, and when combined with […]

The IMerge Phase 3 study (NCT02598661) is a phase 2/3 global study investigating imetelstat, a first-in-class telomerase inhibitor, for patients with red blood cell transfusion-dependent non-del(5q) lower risk-myelodysplastic syndromes (LR-MDS) relapsed/refractory (R/R) to erythropoiesis-stimulating agents (ESAs). We were joined by Dr Rami Komrokji (Moffitt Cancer Center, Tampa, FL, USA) to discuss the unmet needs in […]

BMT-CTN1506 (“MORPHO”) was an international phase III trial investigating the use of post-haematopoietic cell transplantation maintenance with the FLT3 inhibitor, gilteritinib, in patients with FLT3-ITD acute myeloid leukaemia. The aims and findings of the trial, as well as questions that remain to be answered, are discussed in this touchHAEMATOLOGY interview with Dr Mark Levis (Sidney […]

We caught up with Prof Jorge Cortes (Georgia Cancer Center, Augusta University, GA, USA) to discuss his highlights from the recent EHA 2023 Congress, including two clinical trials that investigated the use of quizarpenib in patients with acute myeloid leukaemia. Abstracts discussed: Abstract S130: ‘Preliminary Results of QUIWI: A Double Blinded, Randomized Clinical Trial Comparing […]

The phase II MANIFEST trial (NCT02158858) investigated the use of pelabresib combined with ruxolitinib for patients with myelofibrosis who are JAK inhibitor treatment-naïve. We caught up with Dr John Mascarenhas (Icahn School of Medicine at Mount Sinai, NY, USA), one of our valued Editorial Board members, to discuss the latest durability of response and safety results […]

Myelofibrosis is a complex haematological malignancy for which the current first-line treatment is Janus kinase inhibitors. touchHAEMATOLOGY caught up with one of our valued Editorial Board members, Dr John Mascarenhas (Icahn School of Medicine at Mount Sinai, NY, USA) to discuss the current therapeutic options for myelofibrosis and their limitations. The abstract entitled ‘UPDATED DURABILITY […]

President of the European Oncology Nursing Society, Johan de Munter, discusses the key take-home messages from his Nurses Group Keynote Lecture at the European Society for Blood and Marrow Transplantation (EBMT) annual meeting, 23-26 April 2023. Questions: Please summarise the key points from your Nurses Group Keynote Lecture presented at the EBMT conference 2023 (00:18) […]